Nilesh Jethwa: Reported Adverse Events and Safety Signals With Ofatumumab
Nilesh Jethwa, Founder and CEO at InfoCaptor (Rudrasoft), shared a post on X:
“The adverse event reports for ofatumumab indicate a total of 3,291 reports spanning from July 2024 to June 2026.
The most frequently reported adverse events include febrile neutropenia (500 reports), neutropenia (380 reports), and anemia (320 reports). Among the outcomes, 383 reports were classified as Fatal, while many others were categorized as Unknown or Recovered, suggesting a mix of severity in the reported cases.
Serious reactions frequently included febrile neutropenia and neutropenia, indicating these may be significant concerns. There is a notable difference in the sex breakdown, with more reports from males (1,516) compared to females (1,145).
The reporting trend appears to be stable over the recent months, with fluctuations but no clear rising or falling pattern. Additionally, serious-sounding terms such as hemorrhage and thrombocytopenia were also reported.
It is important to note that these adverse event reports are spontaneous and voluntary, do not establish causation, may contain duplicates, and cannot be used to calculate true incidence or risk.”
Stay updated with Hemostasis Today.
-
Oct 23, 2026, 16:05Platelet Secretion Defects and Their Role in the Diagnosis of Bleeding Disorders
-
Oct 23, 2026, 16:00Hemophilia Alliance team in New Orleans at the ATHN Data Summit
-
Oct 23, 2026, 15:49Brian Sapp: Why Exact Calf Vein Naming Is Critical for DVT Diagnosis?
-
Oct 23, 2026, 15:33Smitirupa Mishra: A Systematic Approach to Bone Marrow Examination
-
Oct 23, 2026, 15:29José Antonio García Erce: Preoperative Anemia Emerges as a Modifiable Surgical Risk in New POWER Study
-
Oct 23, 2026, 15:13Reza Shojaei: Manufactured Red Blood Cells vs Blood Donation
-
Oct 23, 2026, 14:29Jean Jacques Kiladjian: International Scientific Exchange at IHCAMS in Tianjin
-
Oct 23, 2026, 14:11Aravind Palraj: The Prolonged aPTT Puzzle in SLE
-
Oct 23, 2026, 13:56Chokri Ben Lamine: The Evolving Treatment Landscape of Persistent and Chronic ITP